EA201591124A1 - Трансдермальная система доставки - Google Patents

Трансдермальная система доставки

Info

Publication number
EA201591124A1
EA201591124A1 EA201591124A EA201591124A EA201591124A1 EA 201591124 A1 EA201591124 A1 EA 201591124A1 EA 201591124 A EA201591124 A EA 201591124A EA 201591124 A EA201591124 A EA 201591124A EA 201591124 A1 EA201591124 A1 EA 201591124A1
Authority
EA
Eurasian Patent Office
Prior art keywords
buprenorphine
acid
layer
matrix layer
adhesive
Prior art date
Application number
EA201591124A
Other languages
English (en)
Inventor
Габриель Вауер
Кевин Джон Смит
Джиллиан Элизабет Мундин
Хелен Элизабет Джонсон
Томас Хилле
Original Assignee
Лтс Ломанн Терапи-Систем Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49816915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591124(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Лтс Ломанн Терапи-Систем Аг filed Critical Лтс Ломанн Терапи-Систем Аг
Publication of EA201591124A1 publication Critical patent/EA201591124A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к способу лечения боли у пациента посредством нанесения трансдермальной терапевтической системы для трансдермального введения бупренорфина на 7 дней на кожу пациента, причем указанная трансдермальная терапевтическая система содержит слоистую, содержащую бупренорфин самоклеящуюся структуру, содержащую A) непроницаемый для бупренорфина слой-подложку и B) содержащий бупренорфин матричный слой на указанном непроницаемом для бупренорфина слое-подложке, причем матричный слой содержит a) полимерную основу, b) бупренорфин и c) карбоновую кислоту, выбранную из группы, состоящей из олеиновой кислоты, линолевой кислоты, линоленовой кислоты, левулиновой кислоты и их смесей, в количестве, достаточном для того, чтобы указанный бупренорфин солюбилизировался в ней с формированием смеси, а смесь карбоновой кислоты и бупренорфина формировала дисперсные отложения в полимерной основе, и C) контактирующий с кожей слой на указанном содержащем бупренорфин матричном слое, который содержит полимерный склеивающий при надавливании клей, и причем необязательно слоистая, содержащая бупренорфин самоклеящаяся структура содержит указанный бупренорфин в количестве менее 0,8 мг/смоснования бупренорфина или эквимолярное количество его фармацевтически приемлемой соли.
EA201591124A 2012-12-12 2013-12-12 Трансдермальная система доставки EA201591124A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736342P 2012-12-12 2012-12-12
PCT/EP2013/076325 WO2014090921A1 (en) 2012-12-12 2013-12-12 Transdermal delivery system

Publications (1)

Publication Number Publication Date
EA201591124A1 true EA201591124A1 (ru) 2015-11-30

Family

ID=49816915

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591124A EA201591124A1 (ru) 2012-12-12 2013-12-12 Трансдермальная система доставки

Country Status (26)

Country Link
US (3) US20150306093A1 (ru)
EP (1) EP2931263A1 (ru)
JP (1) JP2016502989A (ru)
KR (1) KR20150096460A (ru)
CN (1) CN105007906A (ru)
AP (1) AP2015008525A0 (ru)
AR (1) AR093940A1 (ru)
AU (1) AU2013205080B2 (ru)
BR (1) BR112015013660A2 (ru)
CA (1) CA2894960A1 (ru)
CL (1) CL2015001577A1 (ru)
CR (1) CR20150360A (ru)
DE (1) DE112013005945T5 (ru)
EA (1) EA201591124A1 (ru)
GB (1) GB2523715A (ru)
HK (1) HK1215677A1 (ru)
IL (1) IL239223A0 (ru)
MX (1) MX2015007348A (ru)
NZ (1) NZ628092A (ru)
PE (1) PE20151147A1 (ru)
PH (1) PH12015501169A1 (ru)
SG (1) SG11201504286VA (ru)
TN (1) TN2015000201A1 (ru)
TW (1) TW201438765A (ru)
WO (1) WO2014090921A1 (ru)
ZA (1) ZA201504964B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
MX352795B (es) 2011-12-12 2017-12-07 Lts Lohmann Therapie Systeme Ag Sistema de administracion transdermica que comprende buprenorfina.
GB2529789A (en) 2013-06-04 2016-03-02 Lohmann Therapie Syst Lts Transdermal Delivery system
CN107660207B (zh) 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
WO2017048595A1 (en) * 2015-09-14 2017-03-23 Amneal Pharmaceuticals Llc Transdermal delivery system
KR101695603B1 (ko) * 2016-11-08 2017-01-12 이창우 병목 하단 밀착 구조의 점탄성 연결캡을 포함하는 니들 디스크 롤러 장치
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
JP2021517572A (ja) * 2018-03-13 2021-07-26 エルテーエス ローマン テラピー−ジステーメ アーゲー シリコーンアクリルハイブリッドポリマーを含む経皮治療システム
JP2021515791A (ja) * 2018-03-13 2021-06-24 エルテーエス ローマン テラピー−ジステーメ アーゲー シリコーンアクリルハイブリッドポリマーを含む経皮治療システム
EP3764995A1 (en) * 2018-03-13 2021-01-20 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer
EP3764996A1 (en) * 2018-03-13 2021-01-20 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
BR112021024461A2 (pt) * 2019-07-09 2022-01-18 Lts Lohmann Therapie Systeme Ag Sistema terapêutico transdérmico compreendendo uma camada contendo agente ativo compreendendo um polímero contendo silicone e uma camada de contato com a pele compreendendo um adesivo de gel de silicone
CN113952319A (zh) * 2021-11-30 2022-01-21 烟台大学 一种含丁丙诺啡的骨架型透皮贴剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
NZ539936A (en) * 2002-12-13 2007-06-29 Euro Celtique Sa Transdermal buprenorphine dosage regimen for analgesia
CN1943576A (zh) * 2006-10-27 2007-04-11 哈尔滨健迪医药技术有限公司 丁丙诺啡和/或盐酸丁丙诺啡贴剂基质及其贴剂的制备方法
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
CN101612141B (zh) * 2009-07-29 2012-10-03 考司美德制药株式会社 丁丙诺啡贴剂

Also Published As

Publication number Publication date
US20150306093A1 (en) 2015-10-29
AU2013205080A1 (en) 2014-06-26
CN105007906A (zh) 2015-10-28
NZ628092A (en) 2017-01-27
IL239223A0 (en) 2015-07-30
JP2016502989A (ja) 2016-02-01
ZA201504964B (en) 2017-11-29
MX2015007348A (es) 2016-01-20
CL2015001577A1 (es) 2015-10-02
AR093940A1 (es) 2015-07-01
EP2931263A1 (en) 2015-10-21
GB201512243D0 (en) 2015-08-19
CA2894960A1 (en) 2014-06-19
BR112015013660A2 (pt) 2017-07-11
SG11201504286VA (en) 2015-06-29
CR20150360A (es) 2015-08-21
GB2523715A (en) 2015-09-02
DE112013005945T5 (de) 2015-08-27
US20200253957A1 (en) 2020-08-13
AP2015008525A0 (en) 2015-06-30
PE20151147A1 (es) 2015-08-06
US20180193333A1 (en) 2018-07-12
WO2014090921A1 (en) 2014-06-19
TW201438765A (zh) 2014-10-16
AU2013205080B2 (en) 2016-07-07
HK1215677A1 (zh) 2016-09-09
KR20150096460A (ko) 2015-08-24
PH12015501169A1 (en) 2015-08-10
TN2015000201A1 (en) 2016-10-03

Similar Documents

Publication Publication Date Title
EA201591124A1 (ru) Трансдермальная система доставки
PH12014501231A1 (en) Transdermal delivery system comprising buprenorphine
PH12015502550A1 (en) Transdermal delivery system
MX344241B (es) Sistema terapeutico transdermico para administrar la sustancia activa buprenorfina.
MX2019007391A (es) Sistema terapeutico transdermico que contiene asenapina.
EA201500553A1 (ru) Многодневный пластырь для чрескожного введения ротиготина
MX2009013574A (es) Formas de dosificacion solidas o semisolidas de liberacion modificada.
EA201991014A1 (ru) Лечение диабета
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
EA201300704A1 (ru) Трансдермальная терапевтическая система для введения активного вещества
MX2014002215A (es) Sistema terapeutico transdermico para clorhidrato de acido 5-aminolevulinico.
EA201300648A1 (ru) Трансдермальная терапевтическая система (tts), содержащая ротиготин
IN2015DN01329A (ru)
MY188123A (en) Once-a-day replacement transdermal administration of fentanyl
MX2020014286A (es) Sistema terapeutico transdermico que contiene asenapina.
MX2015010967A (es) Formulaciones transdermicas de laquinimod.
RU2014126635A (ru) Лечение себореи
RU2012146166A (ru) Способ профилактики поражения слизистой оболочки желудка при иммобилизации в эксперименте
WO2014176325A3 (en) Extending and maintaining micropore viability of microneedle treated skin with lipid biosynthesis inhibitors for sustained drug delivery
IN2013DE03033A (ru)
WO2012051213A3 (en) Therapeutic 5,6,5-tricyclic analogs